IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism - PubMed (original) (raw)
IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism
S M Pope et al. J Allergy Clin Immunol. 2001 Oct.
Abstract
Background: IL-13 induces several characteristic features of asthma, including airway eosinophilia, airway hyperresponsiveness, and mucus overproduction; however, the mechanisms involved are largely unknown.
Objective: We hypothesized that IL-13-induced inflammatory changes in the lung were dependent in part on IL-5 and eotaxin, two eosinophil-selective cytokines.
Methods: Recombinant murine IL-13 was repeatedly administered to the lung by intranasal delivery until the characteristic features of asthma developed. To analyze the role of IL-5 and eotaxin, we subjected eotaxin gene-targeted, IL-5 gene-targeted, eotaxin/IL-5-double-deficient, IL-5 transgenic, and wild-type mice of the Balb/C background to the experimental regime.
Results: The induction of IL-13-mediated airway eosinophilia was found to occur independently of eosinophilia in the blood or bone marrow, indicating that IL-13-induced airway inflammation is primarily mediated by local effects of IL-13 in the lung. Eosinophil recruitment into both the lung tissue and bronchoalveolar lavage fluid was markedly attenuated in IL-5-deficient mice in comparison with wild-type controls. Accordingly, IL-13 delivery to IL-5 transgenic mice resulted in a large increase in airway eosinophils in comparison with wild-type mice. Interestingly, IL-13-induced eosinophilia in the bronchoalveolar lavage fluid of eotaxin-deficient mice was not impaired; however, these same mice failed to mount a significant tissue eosinophilia in response to IL-13. Finally, IL-13-induced mucus production was not affected by the presence of IL-5 or eotaxin, suggesting that IL-13-induced mucus secretion is mechanistically dissociated from airway eosinophilia.
Conclusion: Selective components of the IL-13-induced asthma phenotype--airway eosinophilia but not mucus secretion--are differentially regulated by IL-5 and eotaxin. IL-5 is required for IL-13 to induce eosinophilia throughout the lung, whereas eotaxin regulates the distribution of airway eosinophils.
Similar articles
- Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice.
Mould AW, Matthaei KI, Young IG, Foster PS. Mould AW, et al. J Clin Invest. 1997 Mar 1;99(5):1064-71. doi: 10.1172/JCI119234. J Clin Invest. 1997. PMID: 9062365 Free PMC article. - Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity.
Yang M, Hogan SP, Mahalingam S, Pope SM, Zimmermann N, Fulkerson P, Dent LA, Young IG, Matthaei KI, Rothenberg ME, Foster PS. Yang M, et al. J Allergy Clin Immunol. 2003 Nov;112(5):935-43. doi: 10.1016/j.jaci.2003.08.010. J Allergy Clin Immunol. 2003. PMID: 14610483 - Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity.
Sharkhuu T, Matthaei KI, Forbes E, Mahalingam S, Hogan SP, Hansbro PM, Foster PS. Sharkhuu T, et al. Clin Exp Allergy. 2006 Dec;36(12):1575-83. doi: 10.1111/j.1365-2222.2006.02595.x. Clin Exp Allergy. 2006. PMID: 17177681 - Elemental signals regulating eosinophil accumulation in the lung.
Foster PS, Mould AW, Yang M, Mackenzie J, Mattes J, Hogan SP, Mahalingam S, Mckenzie AN, Rothenberg ME, Young IG, Matthaei KI, Webb DC. Foster PS, et al. Immunol Rev. 2001 Feb;179:173-81. doi: 10.1034/j.1600-065x.2001.790117.x. Immunol Rev. 2001. PMID: 11292021 Review. - Airway hyperresponsiveness: first eosinophils and then neuropeptides.
Kraneveld AD, Folkerts G, Van Oosterhout AJ, Nijkamp FP. Kraneveld AD, et al. Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):517-27. doi: 10.1016/s0192-0561(97)00085-4. Int J Immunopharmacol. 1997. PMID: 9637348 Review.
Cited by
- Cytokine profiling of extracellular vesicles isolated from plasma in myalgic encephalomyelitis/chronic fatigue syndrome: a pilot study.
Giloteaux L, O'Neal A, Castro-Marrero J, Levine SM, Hanson MR. Giloteaux L, et al. J Transl Med. 2020 Oct 12;18(1):387. doi: 10.1186/s12967-020-02560-0. J Transl Med. 2020. PMID: 33046133 Free PMC article. - A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, Bradding P, Gauvreau GM, Sumino K, FitzGerald JM, Israel E, Bjermer L, Bourdin A, Arron JR, Choy DF, Olsson JK, Abreu F, Howard M, Wong K, Cai F, Peng K, Putnam WS, Holweg CTJ, Matthews JG, Kraft M, Woodruff PG; CLAVIER Investigators. Austin CD, et al. Clin Exp Allergy. 2020 Dec;50(12):1342-1351. doi: 10.1111/cea.13731. Epub 2020 Oct 4. Clin Exp Allergy. 2020. PMID: 32909660 Free PMC article. Clinical Trial. - Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease.
Nader MA, El-Awady MS, Shalaby AA, El-Agamy DS. Nader MA, et al. Naunyn Schmiedebergs Arch Pharmacol. 2012 Sep;385(9):909-19. doi: 10.1007/s00210-012-0772-9. Epub 2012 Jun 26. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22733167 - Intestinal overexpression of IL-18 promotes eosinophils-mediated allergic disorders.
Verma AK, Kandikattu HK, Manohar M, Shukla A, Upparahalli Venkateshaiah S, Zhu X, Mishra A. Verma AK, et al. Immunology. 2019 Jun;157(2):110-121. doi: 10.1111/imm.13051. Epub 2019 Mar 21. Immunology. 2019. PMID: 30779114 Free PMC article. - IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice.
Leyva-Castillo JM, Yoon J, Geha RS. Leyva-Castillo JM, et al. J Allergy Clin Immunol. 2019 Feb;143(2):619-630.e7. doi: 10.1016/j.jaci.2018.05.032. Epub 2018 Jun 18. J Allergy Clin Immunol. 2019. PMID: 29920352 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases